Clinical findings demonstrate that upadacitinib effectively reduces glucocorticoid use in patients with GCA, suggesting a safer alternative to tocilizumab.
Upadacitinib represents an effective oral alternative to tocilizumab for reducing glucocorticoid burden, particularly in patients with relapsing GCA or in patients with GCA who have an increased risk of glucocorticoid-related toxicity, with less profound suppression of inflammatory markers than tocilizumab.
No takes yet. Share an insight, caveat, or question.
Wolfgang A. Schmidt (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: